Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
RecruitingThis multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.
PhaseNA
TypeInterventional
Age14 Years – 75 Years
WhereLos Angeles, California, United States + 10 more
SponsorInsulet Corporation
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418 · Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
RecruitingTRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
PhaseNA
TypeInterventional
Age55 Years
WhereChandler, Arizona, United States + 124 more
SponsorCleerly, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT07296484 ·
Type 2 Diabetes, Cortisol Excess
RecruitingCAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).
PhasePhase 2
TypeInterventional
Age18 Years
WhereChandler, Arizona, United States + 60 more
SponsorSparrow Pharmaceuticals
▾Tap for detailsClick for full details — eligibility, all locations, contacts EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473 · Diabetes Mellitus, Type 2,
Hypertension, Cardiovascular Diseases
RecruitingThis study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.
PhasePhase 3
TypeInterventional
Age18 Years
WhereAnniston, Alabama, United States + 1141 more
SponsorBoehringer Ingelheim
▾Tap for detailsClick for full details — eligibility, all locations, contacts Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
NCT07428746 · Diabetes Mellitus, Type 2
RecruitingThe goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength. Participants will: * Receive GLP-1 RA therapy as part of their routine clinical care * Complete muscle strength assessments (hand grip strength, Timed Up and Go test) * Provide blood samples for bone turnover markers * Undergo bone mineral density testing
PhasePhase 3
TypeInterventional
Age65 Years
WhereAtlanta, Georgia, United States
SponsorEmory University
▾Tap for detailsClick for full details — eligibility, all locations, contacts Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes
RecruitingThis study will collect sensor data in subjects with T1D or T2D, 2-80 years of age.
PhaseNA
TypeInterventional
Age2 Years – 80 Years
WhereChula Vista, California, United States + 18 more
SponsorMedtronic MiniMed, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
NCT07748208 ·
Breast Cancer, Diabetes Type II
RecruitingThis study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.
PhasePhase 2
TypeInterventional
Age18 Years
WhereClovis, California, United States + 12 more
SponsorHoffmann-La Roche
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336 · Diabetes Mellitus, Type 2
RecruitingThis study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them. Participation in the study will last about 61 weeks.
PhasePhase 3
TypeInterventional
Age10 Years – 17 Years
WhereSacramento, California, United States + 70 more
SponsorEli Lilly and Company
▾Tap for detailsClick for full details — eligibility, all locations, contacts Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
NCT06699810 · Ketosis Prone Diabetes
RecruitingThe goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.
PhasePhase 4
TypeInterventional
Age18 Years
WhereAtlanta, Georgia, United States + 1 more
SponsorEmory University
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886 · Obesity, Overweight
RecruitingThe purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
PhasePhase 3
TypeInterventional
Age18 Years
WhereTuscaloosa, Alabama, United States + 157 more
SponsorEli Lilly and Company
▾Tap for detailsClick for full details — eligibility, all locations, contacts Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes
NCT06735651 · Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Female, Adult
RecruitingThe goal of this clinical trial is to determine the effectiveness of using a freeze-dried wild blueberry powder on cardiometabolic health, cognitive function, and gut microbiota composition in adult women with prediabetes.
PhaseNA
TypeInterventional
Age20 Years – 65 Years
WhereAtlanta, Georgia, United States
SponsorGeorgia State University
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RecruitingThe main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
PhasePhase 3
TypeInterventional
Age10 Years – 17 Years
WhereTucson, Arizona, United States + 50 more
SponsorEli Lilly and Company
▾Tap for detailsClick for full details — eligibility, all locations, contacts Peanuts for Cardiometabolic, Brain, and Intestinal Health
NCT06867198 · Prediabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Cognition
RecruitingThe overall objective of this 14-month randomized crossover study is to seek evidence demonstrating that daily consumption of peanuts and peanut products improve cardiometabolic, cognitive, and intestinal health in a racially diverse prediabetes population.
PhaseNA
TypeInterventional
Age20 Years – 59 Years
WhereAtlanta, Georgia, United States
SponsorGeorgia State University
▾Tap for detailsClick for full details — eligibility, all locations, contacts AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335 ·
Type 2 Diabetes, Cardiovascular Risk
RecruitingThis study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.
PhasePhase 3
TypeInterventional
Age45 Years
WhereBirmingham, Alabama, United States + 329 more
SponsorNovo Nordisk A/S
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
RecruitingThe purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
PhasePhase 3
TypeInterventional
Age18 Years
WhereHuntsville, Alabama, United States + 302 more
SponsorAstraZeneca
▾Tap for detailsClick for full details — eligibility, all locations, contacts Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
NCT07868939 · Weight Loss
RecruitingThis study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
PhasePhase 3
TypeInterventional
Age18 Years
WhereTucson, Arizona, United States + 18 more
SponsorViking Therapeutics, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Diabetes Multimorbidity Typology, Trajectory, and Feasibility of an Audio Diary Mobile Application to Support Self-management
NCT07474376 · Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
RecruitingThe goal of this clinical trial is to evaluate whether an audio diary mobile application (Fabla-diabetesMM) is feasible to use and may support self-management in older adults with type 1 or 2 diabetes and multimorbidity. The main questions it aims to answer are: * Is it feasible to adapt and implement the Fabla-diabetesMM audio diary mobile app among 30 older adults with diabetes and multimorbidity * Does the use of the audio diary mobile app affect self-management outcomes
PhaseNA
TypeInterventional
Age65 Years
WhereAtlanta, Georgia, United States
SponsorEmory University
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374 · Obesity, Overweight, Chronic Weight Management
RecruitingThis is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.
PhasePhase 3
TypeInterventional
Age18 Years – 79 Years
WhereBirmingham, Alabama, United States + 73 more
SponsorGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
▾Tap for detailsClick for full details — eligibility, all locations, contacts Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
NCT07868835 · Weight Loss
RecruitingThis study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.
PhasePhase 3
TypeInterventional
Age18 Years
WhereTucson, Arizona, United States + 19 more
SponsorViking Therapeutics, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058 · Obesity or Overweight,
Type 2 Diabetes Mellitus RecruitingThe purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).
PhasePhase 3
TypeInterventional
Age18 Years
WhereGuntersville, Alabama, United States + 221 more
SponsorHoffmann-La Roche
▾Tap for detailsClick for full details — eligibility, all locations, contacts